^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Brain Cancer

    Related cancers:
    1d
    Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Jan 2026
    Enrollment closed • Trial primary completion date
    |
    IDH wild-type
    |
    temozolomide
    1d
    Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) (clinicaltrials.gov)
    P3, N=94, Recruiting, Tata Memorial Centre
    New P3 trial
    1d
    An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial completion date: Apr 2026 --> Jul 2028 | Trial primary completion date: Apr 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    1d
    NRG-BN001: Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=606, Active, not recruiting, NRG Oncology | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    temozolomide
    1d
    BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM (clinicaltrials.gov)
    P2, N=108, Recruiting, Tata Memorial Centre
    New P2 trial
    |
    IDH wild-type
    |
    temozolomide
    1d
    Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis (clinicaltrials.gov)
    P=N/A, N=42, Recruiting, Jonsson Comprehensive Cancer Center
    New trial
    1d
    C-CERTAS-002: Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve (clinicaltrials.gov)
    P=N/A, N=158, Recruiting, Integra LifeSciences Corporation | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Aug 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    2d
    Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial. (PubMed, Cancer)
    This study shows that combining tislelizumab and low-dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF-based molecular markers reflect genomic evolution and predict prognosis. Increased CD163+ cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF-15 levels may further suppress antitumor immunity, facilitating immune escape.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD163 (CD163 Molecule) • GDF15 (Growth differentiation factor 15)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    2d
    Exploring structural diversity and dynamic stability of small-molecule PRMT5 inhibitors through machine learning-based QSAR and molecular modelling. (PubMed, Mol Divers)
    Analysis of consensus QSAR models identified two highly active PRMT5 inhibitor candidates (CHEMBL4539612 and CHEMBL4577464), with high affinity for binding (- 13.5 to - 13.7 kcal/mol) to the PRMT5 active site and interactions similar to those of the known clinical PRMT5 inhibitor ONAMETOSTAT...Network pharmacology analysis indicated that PRMT5 and its interacting partners are mainly associated with histone arginine methylation and spliceosomal assembly, processes that are frequently dysregulated in MTAP-deficient cancers. These findings suggest CHEMBL4539612 and CHEMBL4577464 as promising scaffolds for the development of selective PRMT5 inhibitors in epigenetic cancer therapy.
    Journal
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    onametostat (JNJ-64619178)
    2d
    Stem Cell-Based Delivery of Immunomodulators for Overcoming Glioblastoma Immune Evasion. (PubMed, Immunology)
    Glioblastoma (GBM) is the most aggressive primary brain tumour in adults, characterised by rapid progression, extensive heterogeneity, and poor outcomes despite surgery, radiotherapy, and temozolomide (TMZ)...Preclinical studies demonstrate promising efficacy, yet challenges remain, including safety concerns, variability in outcomes, and the limited translational relevance of current models. This review provides a concise overview of GSC biology, resistance mechanisms, and emerging stem cell-based interventions, highlighting opportunities and obstacles in developing effective therapies for GBM.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • FGFR (Fibroblast Growth Factor Receptor) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    temozolomide
    2d
    BLU-285-3101: A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling (clinicaltrials.gov)
    P1/2, N=29, Completed, Blueprint Medicines Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA mutation
    |
    Ayvakit (avapritinib)
    3d
    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors (clinicaltrials.gov)
    P1, N=13, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date